medigraphic.com
ISSN 0210-5187 (Electronic)

2008, Number 4

<< Back Next >>

Med Cutan Iber Lat Am 2008; 36 (4)

Screening of depigmenting activity of idebenone

Laguens M, Zeitune G, Reigosa M, Cebrián J, Labarta V, Almiñana N

Language: Spanish
References: 30
Page: 183-188
PDF size: 158.41 Kb.


ABSTRACT

Introduction: Various agents exhibit a depigmenting activity, but their usage presents some risk of local and eventually systemic toxicity; thus, new alternatives for pigmentation disorders and bleaching agents are continuously searching. One of these alternatives could be idebenone, a synthetic analogue to coenzyme Q10.
In order to test idebenone capability to specifically inhibit melanin synthesis, the following experiment was performed:
Material and methods: A continuous cell line of human origin (SK-MEL28) with melanin synthesis capability was exposed for 5 days to different concentrations of idebenone. After 5 days, optical densities in supernatants were measured by means of an spectrophotometer in order to evaluate melanin content and cell viability. Results were expressed as a percentage of non-treated cell cultures. As a comparative control, similar experiments were performed using hydroquinone.
Results: Idebenone inhibits melanin synthesis in SK-MEL28 cells in a dose-dependent manner, being this inhibition stronger than that produced by hydroquinone, but with lesser cytotoxic effects.
Comment: Idebenone shows structural analogies with other melanogenesis inhibitor compounds. This analogy could, in some way, interfere with tyrosinase activity to produce melanin. The high safety of the drug and the efficacy demonstrated herein could put idebenone in the first choice line either for the treatment of pigmentation disorders as well as a bleaching agent.


REFERENCES

  1. Mahe A, Ly F, Aymard G, Dangou J. Skin diseases associated with the cosmetic use of depigmenting products in women from Dakar, Senegal. Br J Dermatol 2003;148:493-500.

  2. Akiu S, Suzuki Y, Asahara T, Fujinuma Y, Fukuda M. Inhibitory effect of arbutin on melanogenesis: Biochemical study on cultured ME-6 melanoma cells ad effect on the UV-induced pigmentation in human skin. Proc Jpn Soc Invest Dermatol 1988;12: 138-9.

  3. Yoshimura K, Harii K, Aoyama T, Iga T. Experience with a strong depigmenting treatment for skin hyperpigmentation in Orientals. Plast Reconstr Surg 2000;105:1097-108.

  4. Yoshimura K, Harii K, Aoyama T, Iga T. A new depigmenting protocol for hyperpigmented skin lesions with a high concentration of alltrans retinoic acid aqueous gel. Aesthetic Plast Surg 1999;23:285-91.

  5. Clarys P, Barel A. Efficacy of topical treatment of pigmentation skin disorders with plant hydroquinone glucosides as assessed by quantitative color analysis. J Dermatol 1998;25:412-4.

  6. Kang W, Chun S, Lee S. Intermittent therapy for melasma in Asian patients with combined topical agents (retinoic acid, hydroquinone and hydrocortisone): clinical and histological studies. J Dermatol 1998;25:587-96.

  7. Tung R, Bergfeld W, Vidimos A, Remzi B. alpha-Hidroxy acid-based cosmetic procedures. Guidelines for patient management. Am J Clin Dermatol 2000;18:81-8.

  8. Grimes P. Melasma: etiologic and therapeutic considerations. Arch Dermatol 1995;131:1453-7.

  9. Jimbow K. Vitiligo: therapeutic advances. Dermatol Clin 1998;16:399-407.

  10. Wester R, Melendres J, Hui X, Cox R, Serranzana S, Zhai H, Quan D et al. Human in vivo and in vitro hydroquinone topical bioavailability, metabolism and disposition. J Toxicol Environ Health A 1998;54:301-17.

  11. Jimbow K, Miura S, Ito Y, Kasuga T, Ito S. Utilization of melanin precursors for experimental chemotherapy of malignant melanoma. Gan To Kagaku Ryoho 1984;11:2125-32.

  12. Dooley T, Godwood R, Kilgore T, Thomasco L. Development of an in vitro primary screen for skin depigmentation and antimelanoma agents. Skin Pharmacol 1994;7:188-200.

  13. Yamada K, Tanaka T, Han D, Senzaki K, Kameyama T, Nabeshima T. Protective effects of idebenone and alpha-tocopherol on betaamyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloid-induced neurotoxicity in vivo. Eur J Neurosci 1999;11:83-90.

  14. Weyer G, Babej-Dolle RM, Hadler D, Hofmann S, Herrmann WM. A controlled study of 2 doses of idebenone in the treatment of Alzheimer’s disease. Neuropsychobiology 1997;36:73-82.

  15. Yamada K, Nitta A, Hasegawa T, Fuji K, Hiramatsu M, Kameyama T, Furukawa Y, et al. Orally active NGF synthesis stimulators: potential therapeutic agents in Alzheimer’s disease. Behav Brain Res 1997;83:117-22.

  16. Bergamasco B, Scarzella L, La Commare P. Idebenone, a new drug in the treatment of cognitive impairment in patients with dementia of the Alzheimer type. Funct Neurol 1994;9:161-8.

  17. Schulz JB, Dehmer T, Schols L, Mende H, Hardt C, Vorgerd M, Bürk K et al. Oxidative stress in patients with Friedreich’s ataxia. Neurology 2000;55:1719-21.

  18. Rustin P, Von Kleist-Retzow JC, Chantrel-Groussard K, Sidi D, Munnich A, Rotig Al. Effect of idebenone on cardiomyopathy in Friedreich’s ataxia: a preliminary study. Lancet 1999;354:4777-9.

  19. Ikejiri Y, Mori E, Ishii K, Yasuda M, Sasaki M. Idebenone improves cerebral mitochondrial oxidative metabolism in a patient with MELAS. Neurology 1996;47:583-5.

  20. Pisano P. Plasma concentrations and pharmacokinetics of idebenone and its metabolites following single and repeated doses in young patients with mitochondrial encephalomyopathy. Eur J Pharmacol 1996;51:167-9.

  21. Yasutaka I, Yasuyuki S, Shigeru T: Idebenone-containing preparation for percutaneous administration. World Patent Number: WO9907355. Publication date 1999-02-18.

  22. Neudecker B, Weiland E, Diedrich F. Topically applied idebenone-containing agent with protective and regenerative effect. US Patent Number US6756045.

  23. Gutzmann H, Hadler D. Sustained efficacy and safety of idebenone in the treatment of Alzheimer’s disease:update on a 2-year double-blind multicentre study. J Neural Transm Suppl 1998;54:301-10.

  24. Nielsen H, Henriksen L, Olsen J. Malignant melanoma among lithographers. Scand J Work Environ Health 1996;22:108-11.

  25. Levin C, Maibach H. Exogenous ochronosis. An update on clinical features causative agents and treatment options. Am J Clin Dermatol 2001;2:213-7.

  26. Lawrence N, Bligard C, Reed R, Perret W. Exogenous ochronosis in the United States. J Am Acad Dermatol 1988;18:1027-11.

  27. Hoshaw R, Zimmerman K, Menter A. Ochronosis-like pigmentation from hydroquinone depigmenting creams in American blacks. Arch Dermatol 1985;12:105-8.

  28. Findlay G, Morrison J, Simson I. Exogenous ochronosis and pigmented colloid milium from hydroquinone depigmenting creams. Br J Dermatol 1975;9:613-22.

  29. Terao M, Tomita E, Oki T, Tabe L, Gianni M, Garattini E. Inhibition of melanogenesis by BMY-28565, a novel compound depressing tyrosinase activity in B-15 melanoma cells. Biochem Pharmacol 1992;43:183-9.

  30. Imekawa G. Analysis of initial melanogenesis including tyrosinase transfer and melanosome differentiation through interrupted melanization by glutathione. J Invest Dermatol 1989;93:100-7.




2020     |     www.medigraphic.com